Correlation between Angiogenesis and p53 Expression in Lung Adenocarcinoma of Young Patients

VEGF-A and its isoform VEGF121 mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study

“…In the current study, VEGF-A mRNA level had a significantly positive correlation with VEGF 121 mRNA level, and the high expressions of VEGF-A and VEGF 121 mRNA were correlated with younger age (B65 years old) and tumor dedifferentiation (moderately or poorly differentiated). These results are compatible with previous reports [22,23]. The high expressions of VEGF-A and VEGF 121 mRNA were also correlated with high FDG uptake (SVC-SUV: C5.46), and aggressiveness ( Table 1).…”

A Higher CD105-Assessed Microvessel Density and Worse Prognosis in Elderly Patients With Laryngeal Carcinoma

“…When observational clinical studies were considered, there were reports of fewer blood vessels in breast cancers and lung adenocarcinomas occurring in elderly patients than in younger patients. [17][18][19] Conversely, the present study on CD105-assessed MVD in 57 consecutive cases of LSCC occurring in elderly patients revealed no significant differences vis-à-vis a clinicopathologically homogeneous control group of younger adults. Chandrachud et al 3 also reported findings to indicate that vascularity, as measured by the density or volume of vessels stained with panendothelial markers in 88 resected non-small-cell lung cancers, was unrelated to the patient's age.…”

Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile

“…Considering that concurrent EGFR / TP53 mutations account for over 80% of the EGFR ‐mutant young patients, our report might disclose an important mechanism for poor prognosis and low efficiency of EGFR TKIs in this specific population. It has been reported young patients with lung adenocarcinoma tended to have a poorer prognosis and that angiogenesis of lung adenocarcinoma in young patients was more closely correlated with p53 expression than in elderly patients . Consequently, the combination of erlotinib plus bevacizumab might be an optimal regimen in young patients with concurrent EGFR / TP53 ‐mutant lung adenocarcinoma, warranting further well‐conducted investigation to validate this deduction .…”